Loading…
← CockpitCompetitor Analysis › 002582.SZ Haoxiangni Health Food Co., Ltd. Class AOpen in the cockpit ↗

Haoxiangni Health Food Co., Ltd. Class A002582.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Food: Specialty/Candy
Momentum strong 71
Mkt cap
$566M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$39.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-6.2 pp
WACC 5.7%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥9.67
1D+1.8%
1W-3.8%
1M+6.0%
3M-15.9%
6M-20.3%
YTD-12.5%
1Y-3.4%
ATR %3.6%
52w lowhigh41.6% off high

What Haoxiangni Health Food does

Employees: 1,865

Haoxiangni Health Food at a glance

Size Haoxiangni Health Food (002582.SZ) is a China Consumer Staples company (Food: Specialty/Candy) with a market value of $566M, the 3395th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.67 on 18 Nov 2026.

Performance Over six months the shares fell 20.3%, against -10.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 17.0% over the last twelve months (peer median +7.2%); the operating margin is -11.2% (peer median 6.6%).

Valuation It trades at 3.0× enterprise value to sales against a peer median of 1.1× (3rd most expensive of 21).

Capital Return on invested capital runs 6.2 points below its cost of capital (5.7% WACC).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 91002582.SZ 80
Six months, rebased to 100: Haoxiangni Health Food against the median of its 20 peers (local-currency closes).

Haoxiangni Health Food financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.29BCN¥1.32BCN¥1.64BCN¥1.73BCN¥1.40B
Revenue growth—-19%-5%+23%—
Gross profitCN¥477MCN¥317MCN¥308MCN¥412MCN¥287M
EBITDAn/aCN¥85.7MCN¥19.7MCN¥52.9M-CN¥97.9M
Net incomeCN¥2.04BCN¥866M-CN¥72.0M-CN¥51.9M-CN¥189M
Free cash flow-CN¥28.6MCN¥63.4MCN¥53.5MCN¥364M-CN¥268M
Capital expenditureCN¥78.7MCN¥116MCN¥125MCN¥88.6MCN¥130M
Total debtCN¥1.28BCN¥891MCN¥828MCN¥954MCN¥540M

Quarterly statements and history in the cockpit →

Haoxiangni Health Food competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%3009083009736030200029916037774526VADILALIND22206053000022866036979279002166OFRMYASHO2003001680HNDFDSGAEL002582.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Haoxiangni Health Food is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%1×2×3×3009083009736030200029916037774526VADILALIND22206053000022866036979279002166OFRMYASHO2003001680HNDFDS2208GAEL002582.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Haoxiangni Health Food is the large dot.

Haoxiangni Health Food competitors and peer comparison

How Haoxiangni Health Food compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Haoxiangni Health Food against its 20 peers (data as of 18 Nov 2026)
Measure002582.SZPeer medianRank in peer set
1-month return+6.0%-3.3%5th highest of 21
6-month return-20.3%-10.0%6th lowest of 21
Distance from 52-week high-41.6%-25.7%6th lowest of 21
Revenue growth (TTM)-17.0%+7.2%lowest of 21
Operating margin-11.2%6.6%lowest of 21
EV / Sales3.0×1.1×3rd most expensive of 21
ROIC minus cost of capital-6.2 pp+0.9 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Haoxiangni Health Food 002582.SZChina$566M-20%-17%-11%3.0×n/an/a
Zhongjing Food 300908.SZChina$564M-37%+6%19%3.1×6.5%+8.3%
Ligao Foods 300973.SZChina$563M-21%+5%7%1.0×n/an/a
Apple Flavor & Fragrance 603020.SSChina$553M-9%+11%4%1.0×n/an/a
Ganyuan Foods 002991.SZChina$551M-16%0%10%1.4×4.8%+12.4%
Shanghai Laiyifen 603777.SSChina$590M-40%-3%-5%0.8×35.2%-0.9%
Riken Vitamin 4526.TJapan$538M+35%+4%6%0.8×-2.0%+4.4%
Vadilal Industries VADILALIND.NSIndia$536M+63%+36%16%2.8×15.6%+26.5%
Kameda Seika 2220.TJapan$535M+3%+17%6%0.8×0.6%+6.0%
Jiahe Foods Industry 605300.SSChina$604M-15%-7%1%1.1×18.0%+3.7%
Baolingbao Biology 002286.SZChina$515M-6%+7%5%1.2×4.6%+6.0%
YouYou Foods 603697.SSChina$639M-11%+30%11%1.9×3.1%+7.8%
Gift 9279.TJapan$649M+18%+24%11%2.5×n/an/a
Guilin Layn Natural Ingredients 002166.SZChina$652M-32%+7%10%2.6×7.6%+21.1%
Once Upon a Farm, PBC OFRMUnited States$481M-29%+38%-7%1.2×n/an/a
Yasho Industries YASHO.NSIndia$480M+106%+55%15%4.6×34.8%+17.7%
Nitto Fuji Flour Milling 2003.TJapan$466M+12%0%6%0.9×0.1%+5.2%
Daesang 001680.KSSouth Korea$463M-19%+2%4%0.4×-5.3%+7.2%
Hindustan Foods HNDFDS.NSIndia$698M+3%+19%7%1.7×n/an/a
Bourbon 2208.TJapan$456M+4%+7%6%0.5×-12.1%+0.3%
Gujarat Ambuja Exports GAEL.NSIndia$707M-11%+16%10%1.1×n/an/a

Questions

Which companies are Haoxiangni Health Food's closest peers?
The cockpit's peer set: Zhongjing Food (300908.SZ), Ligao Foods (300973.SZ), Apple Flavor & Fragrance (603020.SS), Ganyuan Foods (002991.SZ), Shanghai Laiyifen (603777.SS), Riken Vitamin (4526.T), Vadilal Industries (VADILALIND.NS), Kameda Seika (2220.T).
Is Haoxiangni Health Food expensive compared with its peers?
On ev / sales it trades at 3.0× against a peer median of 1.1×, 3rd most expensive of 21 in its peer set.
How has Haoxiangni Health Food stock performed?
Over six months to 18 Nov 2026 the shares returned -20.3% against -10.0% for the median peer; over one year -3.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.